Acumen Pharmaceuticals(ABOS)
$0.21-0.00 (-1.83%)
ABOS
Acumen Pharmaceuticals financials statements
$0.21
At close:-0.00 (-1.83%)
Want to see ABOS full AI Analyst Report?
Acumen Pharmaceuticals (ABOS) Ratios
719 Followers
Acumen Pharmaceuticals Ratios
ABOS's free cash flow for Q3 2026 was $-26.65M. For the 2026 fiscal year, ABOS's free cash flow was increased by $0.00 and operating cash flow was $-26.65M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.07 | 6.46 | 19.01 | 23.08 | 38.60 |
| Quick Ratio | 4.07 | 6.45 | 19.01 | 23.06 | 38.60 |
| Cash Ratio | 1.80 | 1.29 | 5.16 | 16.65 | 23.73 |
| Solvency Ratio | -2.31 | -1.79 | -1.21 | -5.46 | -19.55 |
| Operating Cash Flow Ratio | -3.85 | -3.12 | -3.32 | -4.50 | -3.49 |
| Short-Term Operating Cash Flow Coverage | -13.18 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 69.85M | $ 121.13M | $ 203.46M | $ 172.52M | $ 193.51M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.25 | 0.12 | 0.09 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.44 | 0.16 | 0.11 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.31 | 0.14 | 0.10 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.24 | 0.14 | 0.09 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.74 | 1.31 | 1.16 | 1.04 | 1.02 |
| Debt Service Coverage Ratio | -9.00 | -24.11 | -88.82 | 0.00 | 0.00 |
| Interest Coverage Ratio | -29.32 | -28.03 | -105.23 | 0.00 | 0.00 |
| Debt to Market Cap | 0.24 | 0.29 | 0.15 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.59 | 0.56 | 0.60 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.19 | 0.06 | 0.74 | 3.05 | 6.24 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.98% | 89.75% | 85.66% | 94.74% | 513.72% |
| Return on Assets (ROA) | -98.78% | -42.82% | -16.89% | -21.80% | -43.68% |
| Return on Equity (ROE) | -172.28% | -56.28% | -19.62% | -22.70% | -44.68% |
| Return on Capital Employed (ROCE) | -133.40% | -53.94% | -20.57% | -23.96% | -8.70% |
| Return on Invested Capital (ROIC) | -121.71% | -53.90% | -20.51% | -23.95% | -8.70% |
| Return on Tangible Assets | -98.80% | -42.82% | -16.90% | -21.80% | -43.68% |
| Earnings Yield | -94.95% | -99.13% | -28.13% | -19.55% | -38.89% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 11.31 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | -32.27 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 32.27 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.91 | -1.44 | -0.89 | -0.87 | -0.47 |
| Free Cash Flow Per Share | -1.91 | -1.44 | -0.89 | -0.87 | -0.47 |
| Dividend Paid and CapEx Coverage Ratio | -1312.93 | -5388.44 | -2050.67 | -218.34 | -449.02 |
| Capital Expenditure Coverage Ratio | -1312.93 | -5388.44 | -2050.67 | -218.34 | -449.02 |
| Operating Cash Flow Coverage Ratio | -3.69 | -2.90 | -1.51 | -334.79 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -90.48% | -83.54% | -23.14% | -16.11% | -6.96% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.05 | -1.01 | -3.56 | -5.12 | -2.57 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.81 | 0.57 | 0.70 | 1.16 | 1.15 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.11 | -1.20 | -4.32 | -6.21 | -14.37 |
| Price-to-Operating Cash Flow Ratio | -1.11 | -1.20 | -4.32 | -6.24 | -14.40 |
| Price-to-Earnings Growth (PEG) Ratio | -0.06 | -0.02 | -1.88 | 0.09 | -0.00 |
| Enterprise Value Multiple | -0.90 | -0.99 | -2.86 | -2.09 | -6.97 |
| Enterprise Value | 105.11M | 97.30M | 147.81M | 89.25M | 136.52M |
| EV to EBITDA | -0.90 | -0.99 | -2.86 | -2.09 | -6.97 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.91 | -1.13 | -3.43 | -2.53 | -7.58 |
| EV to Operating Cash Flow | -0.91 | -1.13 | -3.43 | -2.54 | -7.60 |
| Tangible Book Value Per Share | 1.16 | 3.03 | 5.50 | 4.65 | 5.88 |
| Shareholders’ Equity Per Share | 1.16 | 3.03 | 5.51 | 4.65 | 5.88 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.00 | -1.71 | -1.08 | -1.06 | -2.63 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.04 | 1.04 | 1.01 | 1.00 | 5.14 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.95 | 0.84 | 0.82 | 0.82 | 0.18 |
Currency in USD
